natgillin/translations-raw huggingface dataset:
A decrease in the total score indicates an improvement in PBA symptoms. 
Znižanje skupnega rezultata pomeni izboljšanje simptomov PBP.
Treatment should be started with one lower strength capsule (15mg/9mg) once a day (in the morning), which is increased after one week to twice a day (in the morning and evening, 12 hours apart). 
Na začetku zdravljenja se jemlje eno kapsulo manjše jakosti (15 mg/9 mg) enkrat na dan (zjutraj), po enem tednu pa je treba odmerek povečati na dve kapsuli na dan (zjutraj in zvečer, z 12-urnim presledkom).
A risk management plan has been developed to ensure that Nuedexta is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Nuedexta je bil pripravljen načrt obvladovanja tveganj.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Nuedexta's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Nuedexta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The most common side effects with Nuedexta (which may affect up to 1 in 10 people) are diarrhoea, nausea (feeling sick), dizziness, headache, somnolence (sleepiness) and fatigue (tiredness). 
Najpogostejši neželeni učinki zdravila Nuedexta (ki lahko prizadenejo največ 1 osebo od 10) so diareja, navzea (slabost), omotica, glavobol, somnolenca (zaspanost) in utrujenost.
Regarding its safety, the CHMP decided that dextromethorphan and quinidine have been marketed as medicines for a number of years and their safety and interactions with other medicines are relatively well known. 
V zvezi z varnostjo je CHMP ugotovil, da se dekstrometorfan in kinidin kot zdravili tržita že vrsto let in da je glede njune varnosti in medsebojnega delovanja z drugimi zdravili znanega že relativno veliko.
For more information about treatment with Nuedexta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Nuedexta preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Although the exact cause of PBA is unclear, it is believed that it affects the way signals are transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other. 
Čeprav natančen vzrok PBP ni znan, domnevno vpliva na način prenosa signalov med možganskimi celicami, ki poteka s pomočjo „živčnih prenašalcev , tj. kemičnih snovi, ki omogočajo medsebojno komunikacijo med živčnimi celicami.
After 12 weeks of treatment with Nuedexta, the CNS-LS score decreased by 8.2 points, compared with a decrease of 5.7 points for placebo. 
Po 12 tednih zdravljenja z zdravilom Nuedexta se je rezultat na lestvici CNS-LS znižal za 8,2 točke, medtem ko se je pri placebu znižal za 5,7 točke.
What measures are being taken to ensure the safe use of Nuedexta? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Nuedexta?
The company will also carry out a study on the use of Nuedexta and a study to monitor Nuedexta's safety including its effects on the heart and potential for interactions with other medicines. 
Prav tako bo družba izvedla študijo uporabe zdravila Nuedexta in študijo, namenjeno spremljanju varnosti zdravila Nuedexta, vključno z njegovimi učinki na srce in možnostmi medsebojnega delovanja z drugimi zdravili.
• who are already being treated with the medicines quinidine, quinine or mefloquine or who have previously developed certain serious problems such as thrombocytopenia (low platelet counts) due to the use of these medicines; 
• ki se že zdravijo s kinidinom, kininom ali meflokinom ali pri katerih so se v preteklosti že pojavile nekatere resne bolezni, na primer trombocitopenija (majhno število trombocitov), ki so bile posledica uporabe teh zdravil;
Since these neurotransmitters are involved in the control of emotions, dextromethorphan helps to normalise its activity in the brain, reducing the symptoms of PBA. 
Ker ta živčna prenašalca sodelujeta pri uravnavanju čustev, dekstrometorfan pomaga normalizirati dejavnosti v možganih, s čimer se zmanjšajo simptomi PBP.
Nuedexta is available as capsules (15 mg or 23 mg dextromethorphan and 9 mg quinidine) and can only be obtained with a prescription. 
Zdravilo Nuedexta je na voljo v obliki kapsul (15 mg ali 23 mg dekstrometorfana in 9 mg kinidina) in se izdaja le na recept.
In addition, the company that makes Nuedexta must ensure that all healthcare professionals who are expected to use Nuedexta receive an information pack and a patient alert card with key safety information. 
Poleg tega mora družba, ki izdeluje zdravilo Nuedexta, zagotoviti, da bodo vsi zdravstveni delavci, ki naj bi uporabljali zdravilo Nuedexta, prejeli informativni paket ter opozorilno kartico za bolnike s ključnimi informacijami o varnosti.
It is used to treat the symptoms of pseudobulbar affect (PBA) in adults. 
Uporablja se za zdravljenje simptomov psevdobulbarne paralize (PBP) pri odraslih.
Treatment with Nuedexta was effective in reducing patients' PBA episodes which were reduced by nearly 50% more than in patients treated with placebo. 
Zdravljenje z zdravilom Nuedexta je bilo učinkovito pri zmanjšanju števila epizod PBP, ki so se zmanjšale za skoraj 50 % bolj kot pri bolnikih, zdravljenih s placebom.
Dextromethorphan / quinidine 
Nuedexta dekstrometorfan/kinidin
What benefits of Nuedexta have been shown in studies? 
Kakšne koristi je zdravilo Nuedexta izkazalo v študijah?
What is Nuedexta and what is it used for? 
Kaj je zdravilo Nuedexta in za kaj se uporablja?
Although the exact way dextromethorphan works in PBA is unclear, it attaches to several different nerve cell receptors in the brain such as NMDA receptors and sigma-1 receptors for the neurotransmitter glutamate as well as receptors for the neurotransmitter serotonin. 
Natančen način delovanja dekstrometorfana pri PBP ni znan, se pa veže na več različnih živčnih receptorjev v možganih, kot so receptorji NMDA in receptorji sigma-1 za živčni prenašalec glutamat ter receptorji za živčni prenašalec serotonin.
Nuedexta has been studied in one main study involving 326 patients with PBA due to multiple sclerosis or amyotrophic lateral sclerosis. 
Zdravilo Nuedexta so raziskali v eni glavni študiji, v katero je bilo vključenih 326 bolnikov s PBP, ki je bila posledica multiple skleroze ali amiotrofične lateralne skleroze.
• with or at high risk of complete AV block (a type of heart rhythm disorder); 
• ki imajo ali pri katerih obstaja veliko tveganje za kompletni AV-blok (vrsto motnje srčnega ritma);
The role of quinidine is to prevent dextromethorphan from being broken down early in the body and thereby it prolongs the action of dextromethorphan in the body. 
Naloga kinidina je, da prepreči prehitro razgradnjo dekstrometorfana v telesu in tako podaljša čas njegovega delovanja.
Nuedexta is a medicine that contains two active substances, dextromethorphan and quinidine. 
Nuedexta je zdravilo, ki vsebuje dve zdravilni učinkovini - dekstrometorfan in kinidin.
• with a history suggestive of torsades de pointes ventricular tachycardia (abnormal heart rhythms); 
• z anamnezo, ki kaže na ventrikularno tahikardijo tipa torsades de pointes (nenormalen srčni ritem);
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nuedexta. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Nuedexta, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What is the risk associated with Nuedexta? 
Kakšna tveganja so povezana z zdravilom Nuedexta?
Why has Nuedexta been approved? 
Zakaj je bilo zdravilo Nuedexta odobreno?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Nuedexta, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo Nuedexta vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Nuedexta was compared with placebo (a dummy treatment) for 12 weeks. 
Zdravilo Nuedexta so 12 tednov primerjali s placebom (zdravilom brez zdravilne učinkovine).
For the full list of all side effects reported with Nuedexta, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Nuedexta, glejte navodilo za uporabo.
How does Nuedexta work? 
Kako zdravilo Nuedexta deluje?
How is Nuedexta used? 
Kako se zdravilo Nuedexta uporablja?
The CHMP concluded that Nuedexta is effective in treating the symptoms of PBA based on the studies in patients with PBA caused by multiple sclerosis and amyotrophic lateral sclerosis. 
Na podlagi študij pri bolnikih s PBP, ki je bila posledica multiple skleroze in amiotrofične lateralne skleroze, je zaključil, da je zdravilo Nuedexta učinkovito pri zdravljenju simptomov PBP.
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
Arquiparque-Miraflores 1495-131 Algés Portugal 
Arquiparque-Miraflores 1495-131 Algés Portugalska
266 Kifisias Avenue 152 32 Halandri Greece 
266 Kifisias Avenue 152 32 Halandri Grčija
GlaxoSmithKline Latvia SIA Duntes iela 11 
GlaxoSmithKline Latvija SIA Duntes iela 11
GlaxoSmithKline, S.A. PTM- Severo Ochoa, 2 28760-Tres Cantos (Madrid) Spain 
GlaxoSmithKline, S.A. PTM- Severo Ochoa, 2 28760-Tres Cantos (Madrid) Španija
1 g/vial 
1 g/viala
Intramuscular 
Intramuskularno
Powder for oral suspension (sachet) 
Prašek za peroralno suspenzijo (vrečica)
Intravenous/ Intramuscular 
Intravensko/Intramuskul arno
Intramuscular Use 1 g/vial 
Intramuskularna uporaba 1 g/viala
Amoxil Vials 500mg, powder for solution for injection or infusion 
Amoxil Vials 500mg, powder for solution for injection or infusion powder for solution for injection or infusion
Dispersible tablet 
Disperzibilna Tableta Peroralna uporaba
Amoxil Paediatric 125mg/1.25ml Powder for Oral Suspension 
Paediatric 125mg/1.25m l Powder for Oral
Amoxil 3g Powder for Oral Suspension Sachets 
Amoxil 3g Powder for Oral
Intravenous 
Intravensko
500 mg Capsule 
500 mg Kapsula
500 mg Capsule, hard 
500 mg Kapsula, trda
Stonemasons Way Rathfarnham Dublin 16 
GlaxoSmithKline (Irska) Ltd Stonemasons Way Rathfarnham
Powder for solution for injection 
Prašek za raztopino za injiciranje
Amoxil Capsules 500mg 500 mg Capsule 
Amoxil Kapsulas 500mg
Powder and solvent for solution for injection 
Prašek in topilo za raztopino za injiciranje
United Kingdom250 mg Capsule 
250 mg Kapsula
Apo B decreased by 12%. 
Koncentracija Apo B se je znižala za 12 %.
Very rare: Pancreatitis 
Zelo redko: pankreatitis
The safety and efficacy in children (below the age of 18 years) has not been studied. 
Varnost in učinkovitost tega zdravila pri otrocih (mlajših od 18 let) ni bila preučevana.
Other forms of interaction 
Druge oblike medsebojnega delovanja
Without the recycling process, your liver has to make additional bile acids. 
Brez postopka ponovne uporabe morajo vaša jetra ustvariti dodatne žolčne kisline.
Date of first authorisation: 10 March 2004 Date of latest renewal: 12 March 2009 
Datum zadnjega podaljšanja: 12. marec 2009
Doses in excess of the maximum recommended dose (4.5 g per day (7 tablets)) have not been tested. 
Odmerkov, večjih od najvišjega priporočenega odmerka (4,5 g dnevno (7 tablet)), niso preizkusili.
You may take your dose with a later meal, but never take in one day more than the total number of tablets that your doctor has prescribed to you in a single day. 
Lahko vzamete odmerek ob kasnejšem obroku, vendar nikoli ne vzemite več od skupnega števila tablet, ki vam jih je zdravnik predpisal za en dan.
The medicines may be taken at the same time or at separate times according to what your doctor has prescribed. 
Zdravila boste morda jemali istočasno ali pa ob različnih časih, odvisno od tega, kaj vam je predpisal zdravnik.
A total of 85% of the patients were on either atorvastatin (50% of whom received 80 mg dose) or rosuvastatin (72% of whom received 40 mg dose). 
Skupno 85 % bolnikov je prejemalo bodisi atorvastatin (50 % od njih je prejemalo odmerek 80 mg) bodisi rosuvastatin (72 % od njih je prejemalo odmerek 40 mg).
The reporting rate is classified as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). 
Navedba pogostosti neželenih učinkov je označena kot zelo pogosto (≥1/10), pogosto (≥1/100 do <1/10), občasno (≥1/1.000 do <1/100), redko (≥1/10.000 do <1/1.000), zelo redko (<1/10.000) in kot neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
In general 
Splošno
Since Cholestagel is not absorbed, the risk of systemic toxicity is low. 
Ker se zdravilo Cholestagel ne absorbira, je tveganje sistemske toksičnosti nizko.
* see section below for further information ** adverse reactions from post-marketing experience 
* za več informacij glejte poglavje spodaj ** neželeni učinki iz obdobja po prihodu na trg
The safety and efficacy of Cholestagel in children aged 0 to 17 years have not yet been established. 
Varnost in učinkovitost zdravila Cholestagel pri otrocih, starih 0 do 17 let, še nista bili dokazani.
The tablets should be swallowed whole and not broken, crushed or chewed. 
Tablete je treba pogoltniti cele in se jih ne sme deliti, drobiti ali žvečiti.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you. 
Pred začetkom jemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
When administering medicinal products for which alterations in blood levels could have a clinically significant effect on safety or efficacy, physicians should consider monitoring serum levels or effects. 
Pri uporabi zdravil, pri katerih spremembe koncentracije v krvi lahko klinično značilno vplivajo na varnost ali učinkovitost, bi morali zdravniki spremljati koncentracije v serumu ali učinke.
Cholestagel did not induce any clinically significant reduction in the absorption of vitamins A, D, E or K during clinical studies of up to one year. 
Cholestagel ni povzročil klinično pomembnega zmanjšanja absorpcije vitaminov A, D, E ali K med kliničnimi študijami, ki so trajale do enega leta.
A concomitant increase in very low density lipoprotein synthesis can occur. 
Hkrati se lahko poveča sinteza lipoproteinov zelo nizke gostote.
The MAH shall perform the pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Your doctor may increase your dose to 7 tablets per day. 
Zdravnik vam bo morda povečal odmerek na 7 tablet dnevno.
Secondary causes of hypercholesterolaemia 
Sekundarni vzroki hiperholesterolemije
Cholestagel may affect the way in which the following medicines work: 
Zdravilo Cholestagel lahko vliva na delovanje naslednjih zdravil:
Do not use this medicine after the expiry date which is stated on the carton and bottle label after “EXP'' 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki na škatli in plastenki poleg oznake "Uporabno do".
The effects of combination of fenofibrate and Cholestagel on the risks of myopathy or hepatotoxicity are not known. 
Učinki kombinacije fenofibrata in zdravila Cholestagel na tveganje za miopatijo ali hepatotoksičnost niso poznani.
What Cholestagel is and what it is used for 
Kaj je zdravilo Cholestagel in za kaj ga uporabljamo
6.6 Instructions precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Common: Headache 
Pogosto: glavobol
Therefore advice is given to closely monitor ciclosporin blood concentrations (see also section 4.4). 
Svetujemo, da pozorno nadzorujete vrednosti ciklosporina v krvi (glejte tudi poglavje 4.4).
Manufacturer Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland 
Izdelovalec Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska
Safety and efficacy are not established for patients with triglyceride levels greater than 3.4 mmol/L, since such patients were excluded from the clinical studies. 
Varnost in učinkovitost uporabe še nista potrjeni pri bolnikih, ki imajo koncentracije trigliceridov nad 3,4 mmol/L, ker so bili taki bolniki izključeni iz kliničnih študij.
A study conducted in rats did not result in any differences in reproductive parameters between the groups that might imply reproductive effects attributable to colesevelam. 
Študije na podganah niso pokazale kakršnihkoli razlik v reproduktivnih parametrih med skupinami, ki bi lahko kazale na učinke na razmnoževanje in jih je mogoče pripisati holesevelamu.
If you need to take other medicines more than once a day, remember that your Cholestagel tablets can be taken once a day. 
Če morate vzeti druga zdravila več kot enkrat na dan, je pomembno, da si zapomnite, da lahko tablete Cholestagel vzamete enkrat na dan.
Not known: Intestinal obstruction*,** Musculoskeletal and connective tissue disorders Uncommon: Myalgia 
Neznano: intestinalna obstrukcija*,** Bolezni mišično-skeletnega sistema in vezivnega tkiva Občasno: mialgija
• Oral contraceptives (medicines to prevent pregnancy) It is important you take Cholestagel at least 4 hours after you take the oral contraceptive to ensure that the effectiveness of the contraceptive is not affected. 
• peroralni kontraceptivi (zdravila za preprečevanje nosečnosti) (pomembno je, da vzamete zdravilo Cholestagel najmanj 4 ure potem, ko ste vzeli peroralno kontracepcijsko tabletko, da ne bi zmanjšali učinkovitosti kontracepcijske tabletke),
Your doctor may stop your medicine. 
Zdravnik se bo morda odločil, da morate prenehati jemati zdravilo.
Monitoring of the clinical effects of treatment with ursodeoxycholic acid should be considered. 
Razmisliti morate o spremljanju kliničnih učinkov zdravljenja z ursodeoksiholno kislino.
• Verapamil or olmesartan (medicines used to treat high blood pressure). 
• verapamil ali olmesartan (zdravili za zdravljenje visokega krvnega tlaka).
In controlled clinical studies involving approximately 1400 patients and during post-approval use, the following adverse reactions were reported in patients given Cholestagel. 
V kontroliranih kliničnih študijah, v katerih je sodelovalo približno 1400 bolnikov, in v obdobju trženja zdravila so poročali o naslednjih neželenih učinkih pri bolnikih, ki so prejemali zdravilo Cholestagel.
Furthermore, Cholestagel should always be administered at the same times consistently since the timing of intake of Cholestagel and ciclosporin could theoretically influence the degree of reduced bioavailability of ciclosporin. 
Nadalje naj se zdravilo Cholestagel vedno dosledno jemlje ob istem času, saj lahko časovni razpored jemanja zdravila Cholestagel in ciklosporina teoretično vpliva na stopnjo zmanjšane biološke uporabnosti ciklosporina.
HDL-C and hsCRP levels were also not significantly different compared to placebo at 12 weeks. 
Koncentraciji holesterola HDL in hsCRP se v primerjavi s placebom po 12 tednih prav tako nista pomembno razlikovali.
Cholestagel has no or negligible influence on the ability to drive and use machines. 
Zdravilo Cholestagel nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Description of selected adverse events 
Opis izbranih neželenih dogodkov
If you take a medicine called either Neoral® or ciclosporin, please ensure to take it with Cholestagel in a consistent pattern over the day; either always together or always separate for a set number of hours. 
Če jemljete zdravilo z imenom Neoral® oziroma ciklosporin, ga morate jemati z zdravilom Cholestagel dosledno skladno s predpisanim dnevnim odmerjanjem: ali vedno skupaj ali vedno v predpisanem razmaku števila ur.
• Antidiabetic medications (medicines used to treat diabetes, such as metformin extended-release (ER) tablets, glimepiride, glipizide, pioglitazone, repaglinide or glyburide). 
• antidiabetična zdravila (zdravila za zdravljenje sladkorne bolezni, kot so metformin v obliki tablet s podaljšanim sproščanjem (ER extended-release), glimepirid, glipizid, pioglitazon, repaglinid ali gliburid).
If you are going to take Cholestagel and one of these medicines, your doctor may want to do tests to make sure that Cholestagel does not interfere with these medicines. 
Če boste jemali zdravilo Cholestagel in katero od teh zdravil, bo zdravnik morda želel opraviti teste, da bi se prepričal, da zdravilo Cholestagel ne ovira njihovega delovanja.
It is important to ensure that Cholestagel is administered at least 4 hours after the oral contraceptive pill to minimise the risk of any interaction (see also section 4.5). 
Pomembno je zagotoviti, da se zdravilo Cholestagel vzame najmanj 4 ure po jemanju peroralnih kontracepcijskih tabletk za zmanjšanje tveganja kakršnegakoli medsebojnega vplivanja (glejte tudi poglavje 4.5).
The risk of constipation should especially be considered in patients with coronary heart disease and angina pectoris. 
Na nevarnost obstipacije morate biti posebno pozorni pri bolnikih s koronarno srčno boleznijo in z angino pektoris.
A major portion of bile acids is then absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. 
Večji del se jih nato absorbira iz prebavil in vrne v jetra prek enterohepatičnega obtoka.
No clinical data are available on the use of Cholestagel in pregnant women. 
Klinični podatki o uporabi zdravila Cholestagel pri nosečnicah niso na voljo.
However, formal interaction studies with ursodeoxycholic acid have not been performed. 
Formalne študije interakcij z ursodeoksiholno kislino niso bile opravljene.
Cholestagel may affect the bioavailability of other medicinal products. 
Zdravilo Cholestagel lahko vpliva na biološko uporabnost drugih zdravil.
If you are prescribed Cholestagel and a statin together it is important that you tell your doctor if you are pregnant or if you are planning to become pregnant because statins must not be used during pregnancy; the patient information leaflet that comes with that particular statin should be consulted. 
Če so vam skupaj predpisali zdravilo Cholestagel in statin, je pomembno, da poveste zdravniku, če ste noseči ali če nameravate zanositi, kajti statinov med nosečnostjo ne smete jemati; pozorno preberite navodilo za uporabo določenega statina.